Literature DB >> 9651707

Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure?

J V McMurray1, T A McDonagh, A P Davie, J G Cleland, C M Francis, C Morrison.   

Abstract

A programme to detect and treat asymptomatic left ventricular dysfunction would seem to fulfil all five principles of screening. Indeed, such a programme would appear to be at least as firmly based as those already in existence for, for example, cervical and breast cancer. Further evaluation of the screening of high risk groups to detect asymptomatic left ventricular systolic dysfunction with the aim of giving treatment to prevent the development of heart failure is merited.

Entities:  

Mesh:

Year:  1998        PMID: 9651707     DOI: 10.1093/eurheartj/19.6.842

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  18 in total

Review 1.  Screening for left ventricular dysfunction in the community: role of hand held echocardiography and brain natriuretic peptides.

Authors:  R Senior; G Galasko; J V McMurray; J Mayet
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

2.  Summary of scientific evidence.

Authors: 
Journal:  Occas Pap R Coll Gen Pract       Date:  2002-02

3.  High-sensitivity C-reactive protein as an independent predictor of progressive myocardial functional deterioration: the multiethnic study of atherosclerosis.

Authors:  Eui-Young Choi; Raymond T Yan; Veronica R S Fernandes; Anders Opdahl; Antoinette S Gomes; Andre L C Almeida; Colin O Wu; Kiang Liu; Jeffrey J Carr; Robyn L McClelland; David A Bluemke; Joao A C Lima
Journal:  Am Heart J       Date:  2012-07-07       Impact factor: 4.749

4.  Pseudoexfoliation syndrome and asymptomatic myocardial dysfunction.

Authors:  Lovro Bojić; Ratko Ermacora; Stojan Polić; Milan Ivanisević; Zdravko Mandić; Veljko Rogosić; Mladen Lesin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-14       Impact factor: 3.117

Review 5.  Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies.

Authors:  Emile Levy; Pierre Levy
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 6.  Screening for ventricular remodeling.

Authors:  Douglas S Lee; Thomas J Wang; Ramachandran S Vasan
Journal:  Curr Heart Fail Rep       Date:  2006-04

7.  Ethnic differences in the prevalence and aetiology of left ventricular systolic dysfunction in the community: the Harrow heart failure watch.

Authors:  G I W Galasko; R Senior; A Lahiri
Journal:  Heart       Date:  2005-05       Impact factor: 5.994

8.  Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study.

Authors:  R C Davis; F D R Hobbs; J E Kenkre; A K Roalfe; R Hare; R J Lancashire; M K Davies
Journal:  BMJ       Date:  2002-11-16

Review 9.  Current status of the epidemiology of heart failure.

Authors:  W B Kannel
Journal:  Curr Cardiol Rep       Date:  1999-05       Impact factor: 2.931

10.  B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study.

Authors:  Kirsten Bibbins-Domingo; Maria Ansari; Nelson B Schiller; Barry Massie; Mary A Whooley
Journal:  Circulation       Date:  2003-12-08       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.